| Chen Zhinan |
| Published date：2014-05-30 Provided by：School of Science |
|
Chen Zhi-Nan, M.D., Ph.D., academician of Chinese Academy of Engineering,expert in cancer biology and biotech drug. He is the Director of National Translation Scientific Center of Molecule Medicine and the Director of Cell Engineering Research Centre & Department of Cell Biology of the Fourth Military Medical University, National Key Discipline of Cell Biology. He is the DeputyChiefEngineer of National Science and TechnologyMajor Project forSignificant New Drugs Development and Chief scientist of National 973 Program, expert inbiology and medicine technology of National 863 Program,chairman of China Innovative Alliance Translational Medicine and Bio-technology; Vice-Chairman of Chinese Society of Cell Biology,Vice-Chairman ofChinese Pharmaceutical Association,Chairman of Tumor Marker Committee of Chinese Anti-Cancer Association, Chairman of Military Translational Medicine Committee. He is the editor of J Biol Chem and Science in China (C-series: Life Sciences). He was awarded the National Excellent Teacher, National Excellent Scientific and Technological workers,Gold Star of Science and Technology in general logistics department of PLA, Scientific Talent of PLA.
Academician Chen has been engaged in the mechanism and translational research of tumor biomarker CD147 in cancer biologyfor many years. His research findings including: (1) He resolved the crystal structure of extracellular domain of HAb18G/CD147 and its antigen-antibody complex, which revealed three different epitopes involved in the development of cancer, inflammation and malaria. (2) He conducted a series studies in the interaction of CD147 and other molecules and suggested that these interactions play important roles in the invasion and metastasis of hepatoma and lung cancer. (3) He has long been engaged in the translational research of antibody drugs in individualized treatment. In 2007, Licartin (Iodine-131-Labeled Metuximab) injection was approved by SFDA, which is the first antibody drug with independent intellectual property rightin China for the treatment of hepatocellular carcinoma. The clinical result of Licartinwas published in Hepatology, and the article has been cited and commented by many famous journals such as Nature Immunol and Nature Biotech.The second generation of humanizechimeric antibodyMetuzumab used for lung cancer treatment has been registrated for clinical trial in 2013. The effect of the third generation of humanizeantibodyMelizumab in anti-inflammatory, humanizeantibodyMeplazumab in anti-malaria, and the fourthgeneration of humanizeAntibody-Drug Conjugates have been undergo preclinical study. The ?CD147 Immunohistochemical diagnostic kitKaimeiting has been gone on the market in 2013.
He had successively undertaken the National 863Program, 973 Program, National Science and Technology Major Projectand themajor projects of National Natural Science Foundation. Academician Chen has also obtained 23 national invention patents, 4 international patent authorizations (Germany and US). He had published 91 SCI papers,which were cited for over 500 times. As the chief editor, he also wrote7 books.These remarked achievements have won him a second prize of National Scientific and Technological Progress, and 7 first prizes from Military scientific and technological progress award and Shaanxi province science and Technology Progress Award.
Previous：Yao Jianquan
Next： Ma Zhiming
|